A biotechnology pioneer company in developing a novel class of drugs based on Nanoparticle delivery to treat Cancer and Neurological Diseases.

Onselex developed its new drugs based on advanced nanoparticle encapsulation technology.

Onselex Pharmaceuticals' ONX-1006 sophisticated nanomedicine design is tailored to securely encapsulate Paclitaxel (PTX) within a nanoparticle via a stable chemical bond. It ensures specific release to cancer cells while sparing healthy cells, thereby markedly lowering the risk of adverse effects by more than 95 percent based on toxicology data thus far—compared to typical standard chemotherapy treatments—thereby significantly reducing cancer patients' suffering and effectively increasing the likelihood of complete recovery.

Despite many advances in medicine, pancreatic cancer remains elusive with limited treatment options and a dismal prognosis of 75% mortality within a year and 90% within five years. Pancreatic cancer is often diagnosed in late stages with metastasis. Oncology therapeutic community has for decades sought to cure pancreatic cancer with many robust therapeutic attempts but most failed to achieve successful efficacy. However, amazing pre-clinical data of Onselex’s ONX-1006 suggest successful pancreatic treatment is finally within reach. The current standard of care pancreatic cancer therapies are Folfirinox and Abraxane. Unfortunately, Abraxane prolongs life by only an average of about 1.8 months. Because of ineffective treatment, there are not many treatment therapy options for metastatic pancreatic cancer patients. In the xenograft efficacy test, our ONX-1006 achieved a statistically far superior and significant anticancer effect by more than three times compared to Abraxane's existing pancreatic cancer drug. In addition, groundbreaking non-toxicity results indicated it would not cause any harmful treatment-emergent adverse events when our drug is administered to humans. Essentially, most cancer patients will be able to continue normal activities of daily life during cancer treatments. Based on these data, ONX-1006 demonstrates a strong ability to reduce or eliminate tumor size and extend survival rates in pancreatic cancer patients, achieving a 70% five-year survival rate while minimizing or eliminating side effects.

Onselex will continue to invest in technologies to develop next-generation new drugs, focus on technological development, and proudly establish itself as a leader paving the way for the development of next-generation new biological drugs, thus restoring freedom, happiness, and normality to those affected by cancer.

Thank you very much for your support and considerations.

CEO Ernie Shin